Ruane P, Hernandez J, Richmond G, Williams A, Fralich T, Yau L, Hessenthaler S, Lanier ER; International Conference on AIDS.

Int Conf AIDS. 2002 Jul 7-12; 14: abstract no. ThOrB1386.

Tower ID, LA, United States

BACKGROUND: Resistance testing may improve response in ART-experienced subjects. GT and PT testing have some utility in this setting. We tested the ability of the Virco GT and vPT to predict response to open-label ABC-based therapy in ART-experienced subjects. METHODS: 833 ART-naive and experienced subjects were treated in the US with ABC 300mg BID and >/= 2 other AR drugs, and followed for 16 weeks (wks). GT and vPT were done on ART-experienced subjects as per investigator discretion. Subjects with isolates susceptible to ABC and >/= 2 other AR drugs were enrolled. Changes in therapy were allowed as clinically indicated. Virologic responses (ITT, Observed analyses) were assessed at 8 and 16 wks and correlated with BL GT and vPT characteristics. RESULTS: 180 subjects had GT and vPT performed. Median BL vRNA was 4.3 logs; median CD4 count was 315 cells/mm3. 98% of isolates had /= 1 log drop from BL was 71%. At Wk 16, median change in vRNA from BL was -1.33, median CD4 cell increase was 47 and the proportion of subjects with vRNA < 400 c/mL or >/= 1 log drop from BL was 65%. The table shows the proportion of subjects who achieved vRNA <400 c/mL or >/= 1 log drop from BL by BL resistance for ABC (and likely other NRTIs). *Note that all TAM categories are +/- M184V. Notably, overall responses to these multi-switch regimens appeared to be predictable based on GT and vPT results. Additional analysis to include other variables will be presented. CONCLUSIONS: ABC-based therapy, optimized by GT and vPT results, was effective for experienced subjects in clinical practice. [table: see text]

Publication Types:

• Meeting Abstracts

Keywords:

• Antiretroviral Therapy, Highly Active
• CD4 Lymphocyte Count
• CD4-Positive T-Lymphocytes
• Clinical Trials as Topic
• Dideoxynucleosides
• Drug Therapy, Combination
• abacavir
• drug therapy
• therapy
• virology

Other ID:

• GWAIDS0014181

UI: 102251679

From Meeting Abstracts